See reverse side for additional information Interagency Report Control No 0180-DOA-AN

UNITED STATES OFPARTMENT OF AGRICULTURE ANIMAL AND PLANT HEALTH INSPECTION SERVICE

ANNUAL REPORT OF RESEARCH FACILITY

(TYPE OR PRINT)

1. REGISTRATION NO05

32<u>R0005</u>

FORM APPROVED OMB NO. 0579-0036

2. HEADQUARTERS RESEARCH FACILITY (Name and Address, as registered with USDA include Zip Gode) Bristol-Myers Squibb Company

2400 W. Lloyd Expressway

P.O. Box OS

Evansville, IN 47721 Status: Active

NOV 1 8 1999

3. REPORTING FACILITY (List all locations where animals were housed or used in actual research, testing, teaching, or experimentation, or held for these purposes. Attach additional sheets if necessary.)

FACILITY LOCATIONS (Siles)

See Attached

Building 101

conditioned, or held for use in teaching, testing, experiments, research, or surgery but not yet used for such purposes.	which teaching, research, experiments, or tests were conducted involving no pain, distress, or use of pain-relieving drugs.	which experiments, teaching, research, surgery, or tests were conducted involving accompanying pain or distress to the animals and for which appropriate anesthetic, analgesic, or tranquilizing drugs were used.	experiments, research, surgery or tests were conducted involving accompanying pain or distress to the animals and for which the use of appropriate anesthetic, analgesic, or tranquilizing drugs would have adversely affected the procedures, results, or interpretation of the teaching, research, experiments, surgery, or tests. (An explanation of the procedures producing pain or distress in these animals and the reasons such drugs were not used must be attached to this report).	TOTAL NO OF ANIMALS (Cols. C + D + E)
2	10	57	9	76
0	0	0	0 .	0
0	0	0	0	0
0	0	0	0	0
0	3	16	0	19
57	6	12	0	18
0	0	0	0	. 0
0	0	0	0	0
0	0	0	0	0.
0	0	0	0	0 .
	research, or surgery but not yet used for such purposes.	research, or surgery but not yet used for such purposes. 2 10 0	Involving no surgery but not yet used for such purposes.	Tesearch, or surgery but not yet used for such purposes.

- Profession table standards governing the care, treatment, and use of animals, including approvate use of anesthetic, analgesic, and tranquilizing drugs, prior to, during, research, teaching, testing, surgery, or experimentation were followed by this research facility.
- 2). Each principal investigator has considered alternatives to painful procedures
- 3) This facility is adhering to the standards and regulations under the Act, and it has required that exceptions to the standards and regulations be specified and explained by the principal investigator and approved by the Institutional Animal Care and Use Committee (IACUC). A summary of all such exceptions is attached to this annual report. In addition to identifying the IACUC-approved exceptions, this summary includes a brief explanation of the exceptions, as well as the species and number of animals affected.
- The attending veterinarian for this research facility has appropriate authority to ensure the provision of adequate veterinary care and to oversee the adequacy of other aspects of animal care and use

CERTIFICATION BY HEADQUARTES RESEARCH FACILITY OFFICIAL

(Chief Executive Officer or Legally Responsible Institutional Official)

I certify that the above is true, correct, and complete (7 U.S.C. Section 2143)

NAME & TITLE OF OF OF

(Heplaces VS FORM 18-23 (OCT 88), which is obsolete)

APHIS FORM (AUG 91)



Pharmaceutical Research Institute

2400 West Lloyd Expressway: Evansville, IN 47721-0001 812 429-5000

NOV 1 8 1999

Annual Report of Research Facility October 28, 1999 Registration No. 32-R-0005

The 9 dogs included in column "E" were used in routine toxicity studies of new pharmaceutical compounds. During repeat-dose studies these dogs showed marked side effects attributed to the test compound.

These studies were performed in compliance with Good Laboratory Practice Regulations of the Food and Drug Administration. The use of anesthetic, analgesic, or tranquilizer agents was not possible because of their potential interference with the toxicity profile of the new pharmaceutical compounds.

Summary of Exceptions

There were no exceptions to the standards and regulations during this reporting period.